Exercise before breakfast in the fasting state is more beneficial than postprandial morning exercise for improving liver fat and A1c.
https://t.co/8zRdmdPvU9
Another outcomes trial win for GLP-1 medicines now with Semaglutide and the ESSENCE trial in metabolic liver disease with reduction in both inflammation and fibrosis #MASH https://t.co/EE8jGRnU9s
Nakwento ko na dati ito dito sa Twitter (X na pala)- pero ngayon ko lang nailagay sa slides.
Kung gusto talaga nating magkaroon ng madaming travel options, kailangan nating simulan sa paglalakad. Pedestrian dapat ang priority. Pedestrian tayong lahat.
https://t.co/sMsH2Sl4pg
This important study shows three lessons:
🔸Cirrhosis is frequently underdiagnosed.
🔸Alcohol is the leading cause.
🔸HCC is not adequately screened.
Early diagnosis of silent cirrhosis can save lives !
https://t.co/RENULfbDC7
Shout out and appreciation to all our extraordinary Radiology friends who go above and beyond, ask questions about the history, and are willing to look again when asked ! You help us solve mysteries and save lives everyday. Can't imagine doing Liver and GI without you guys!
How many people visiting diabetes clinic have advanced liver fibrosis?
Lots
Laurent went to diabetes clinic and convinced 300 people to get a liver biopsy. 1 of every 3 had advanced fibrosis
These are the people at risk for liver cancer, ascites, encephalopathy #IMTLD2024
MASLD Natural History
* 3% develop major adverse liver events within 2 decades ( 3 out of 100!)
- seems small - but the MASLD burden is Ginormous!
*Estimated progression to Cirrhosis (for those who progress)
F0-F1 --> 3 decades
F2 --> 2 decades
F3 --> 6 years
New data for #intermediate#HCC at #ESMO24 from LEAP-012 trial
👍🏻PFS/ORR benefit for LenvaPembro+TACE (vs TACE)
🤞🏻OS promising
🤝Toxicity acceptable
👉Systemic+TACE as SOC may be close to be a reality!! (2nd +ve study 😉 EMERALD-1)
@myESMO#ESMOAmbassadors@GrupoTTD@EASLnews
TACE +/- lenva + pembro for intermediate-stage HCC
#ESMO24
🔎Phs III LEAP-012
👉ORR 46 vs 33% (RECIST)
👉ORR 71 vs 49% (mRECIST)
👉mPFS 10 vs 14.6 mo
👉mOS not mature
👉AE ≥3 31% vs 71%
🧐strong ORR and PFS data, already practice-changing?
@myESMO#ESMOAmbassadors
Tirzepatide was associated with 48% decreased kidney events compared to GLP1 RA, in a retrospective analysis of 140,308 patients with type 2 diabetes.
Also with:
⬇️ 20% 🫀MACE
⬇️ 42% ☠️all cause mortality
⬇️ 0.34% a1c
⬇️2.9kg body weight
We need full randomized clinical trials before we can make conclusions of clear superiority
https://t.co/lNVh6UmMFY